Adding Lenvatinib to Pembrolizumab Does Not Provide Additional Benefit in Patients with Unresectable Advanced Melanoma By Ogkologos - September 10, 2025 335 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the LEAP-003 study Source RELATED ARTICLESMORE FROM AUTHOR Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up PAXG Significantly Improves EFS Compared with mFOLFIRINOX in Patients with Resectable or Borderline Resectable Pancreatic Ductal Adenocarcinoma EMA Recommends Extension of Therapeutic Indications for Retifanlimab MOST POPULAR Severe Immune-Related Gastroenterocolitis Described After in Utero Exposure to Pembrolizumab November 15, 2023 Use of Immune Checkpoint Inhibitors is Safe and Effective in Patients... May 26, 2023 SABCS 2021: New Research and Updates in Breast Cancer Treatment and... January 20, 2022 Heart Problems: Investigating the Cardiac Side Effects of Cancer Treatments September 21, 2018 Load more HOT NEWS FDA Grants Regular Approval to fam-Trastuzumab Deruxtecan-nxki for Unresectable or Metastatic... Easy Meals at Home A Combination of Savolitinib and Osimertinib Prolongs PFS in Patients with... Safety of Antibiotics in the Context of First-Line Chemo-Immunotherapy for Advanced...
